



Marwan GHOSN, MD, MHHM

Hematology-Oncology

Contact Information

CMC: +961 1 372888 ext 1150

Tel: + 961 1 613 395 or 6

Mobile: +961 3 226 842

Fax: +961 1 613 397

E-Mail: marwan.ghosn@cmc.com.lb

Medical Experience

Professor Marwan Ghosn acquired his medical degree and his post graduate expertise in Hematology and Oncology from Saint-Joseph University, Faculty of Medicine, in Beirut, Lebanon as well as from the University of Paris XI – Kremlin-Bicêtre and Institut Gustave Roussy Cancer Center in France.

He is the Director of the Hematology & Oncology Program and the Chairman of the Public Health & Health Management Department at Saint-Joseph University, Faculty of Medicine in Beirut.

He acquired a Master in Hospital and Health Management from The Higher School of Business, ESA, in Beirut and a Master in the Quality Management of Units for Care Production (MUPS) from the University of Paris VII, Denis Diderot, France.

He is currently the Director of the Cancer Center and the Head of Hematology & Oncology Division at Clemenceau Medical Center, affiliated with Johns Hopkins International in Beirut.

Professor Marwan Ghosn has also served, for more than 12 years, as Chairman of the Hematology-Oncology Department at Hotel-Dieu de France University Hospital in Beirut, where he is actually continuing his clinical, medical and research activities as well as managerial activity acting as Medical Affairs Director for Quality and Patient Safety.

He served as President of the Lebanese Society of Medical Oncology (LSMO) and was member of the Board of the Lebanese Cancer Society (LCS) for many years. He is an active member of several national & international scientific organizations and societies including the American Society of Clinical Oncology (ASCO), the American Association of Cancer Research (AACR), the European Society of Medical Oncology (ESMO), the American Society of Hematology (ASH), The European Hematology Association (EHA), the International Society of Geriatric Oncology (SIOG) and the Arab Medical Association Against Cancer (AMAAC).

He is author and co-author of more than 65 peer-reviewed articles. He also published and gave an extensive number of communications, posters and abstracts at regional and international meetings, as well as several chapters in books in the field of Medical Oncology and Health Care Management. He is the Editor-in-Chief of the “Pan Arab Journal of Oncology” (PAJO) edited by the Arab Medical Association Against Cancer (AMAAC) and has previously served as Editor-in-Chief of the “Cancer Letter” edited by the Lebanese Cancer Society.

Professor Ghosn has special interests in multiple areas including leadership in conducting research and clinical trials in multiple solid tumors. He has an expertise in breast cancer, urologic cancers, gastrointestinal tumors, geriatric oncology domain as well as in patients’ safety and Quality in Healthcare.

Languages

Arabic : Native language.

French : Fluently written and spoken

English : Fluently written and spoken

Publications

1. LARKIN JM, FISHER RA, PICKERING LM, SOHAIB SA, **GHOSN M**, CHRISTMAS T, CORDINER RL, GORE ME. Chromophobe Renal Cell Carcinoma with Prolonged Response to Sequential Sunitinib and Everolimus. *J Clin Oncol* 2011, Jan 18. (Epub ahead of print).
2. **GHOSN M**, BOUTROS C, GEARA S, KATTAN J, NASR F, CHAHINE G, Experience with palliative care in patients with advanced cancer at a tertiary care hospital in a developing country. *Supportive Care Cancer* 2010, Dec 18 [Epub ahead of print].
3. **GHOSN M**, AFTIMOS P, FARHAT FS, KATTAN JG, HANNA C, HADDAD N, NASR F, CHAHINE G. A phase II randomized study comparing navelbine and capecitabine (Navcap) followed either by Navcap or by weekly docetaxel in the first-line treatment of HER-2/neu negative metastatic breast cancer. *Med Oncol* 2010 Dec [Epub ahead of print].
4. AFTIMOS PG, NASR EA, NASR DI, NOUN RJ, NASR FL, **GHOSN MG**, EL HELOU JA, CHAHINE GY. Adjuvant chemotherapy and radiation for gastric adenocarcinoma: an institutional experience. *Radiat Oncol*. 2010 Jun 4; 5(1):50.
5. **GHOSN MG**, HADDAD AC, NASSAR MN, ABADJIAN GA, KARAK FR, AFTIMOS PG. Acute Myeloid Leukemia and Langerhans' cell histiocytosis: Multiple theories for a usual presentation. *Leuk Res*. 2010 Mar;34(3):406-8
6. FARHAT FS, KATTAN J, **GHOSN MG**. Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer. *Expert Rev Anticancer Ther*. 2010 Apr; 10(4):541-8. Review.
7. FARHAT FS, KATTAN J, CHAHINE GY, YOUNES FC, NASR FL, MROUE RM, **GHOSN MG**. Role of low dose Capecitabine combined to Irinotecan in advanced and metastatic gastric cancer. *Med Oncol*. 2010 Sep;27(3):722-7.
8. **M. GHOSN**, F. FARHAT, J. KATTAN, F. YOUNES, F. NASR, W. MOUKADEM, J. GASMI, G. CHAHINE, Sequential vinorelbine – capecitabine followed by docetaxel in advanced breast cancer: Long-term results of a pilot phase II trial. *Cancer Chemotherapy & Pharmacology* 2008, 62: 11-18.
9. Y. ABOU-MOURAD, Z. OTROCK, J. MAKAREM, J. KATTAN, F. FARHAT, R. JALLOUL, W. MOUKADEM, **M. GHOSN**, A. TAHER, A. CHEHAL, A. SHAMSEDDINE. Docetaxel and Irinotecan as First-Line chemotherapy in patients with advanced non-small cell lung cancer: a pilot study. *J Med Liban* 2008; 56 (1): 16 – 21.
10. KATTAN J, NASR F, CHAHINE G, FARHAT F, MOUKADEM W, YOUNES F, YAZBECK N, **M. GHOSN**. Weekly Docetaxel, Zoledronic Acid and Estramustine in Hormone-Refractory Prostate Cancer Patients (HRPC). *Investigational New Drugs* 2008 Feb; 26 (1): 75 – 9.
11. H. KANSO, H. KAZZI, S. ABI-KHALIL, **M. GHOSN**, G. CHAHINE, C TOHME, N AOUN and M. GHOSAIN. Interest of systematic Ultrasound for the scar of mastectomy. *Journal de Radiologie, Tome 88, October 2007*.
12. **M. GHOSN**, F. FARHAT, J. KATTAN, F. YOUNES, W. MOUKADEM, F. NASR, G. CHAHINE. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Hotel-Dieu de France University Hospital, Beirut; Hammoud Hospital, Sidon; Haikal Hospital, Tripoli. For the Cancer Research Group/Collaborative Group, Beirut, Lebanon. *American Journal of Clinical Oncology* 2007, 30 (1): 15-20.
13. **M. GHOSN**, J. KATTAN, F. FARHAT, F. YOUNES, J. GASMI; Phase II trial of Capecitabine and Vinorelbine as first line chemotherapy for metastatic breast cancer patients. Hôtel-Dieu de France University Hospital, Beirut, Lebanon; Hammoud University Hospital Medical Center, Sidon, Lebanon; Institut de Recherche Pierre Fabre, Boulogne, France. Original. *Anticancer Research* 2006, 26: 2451 – 6. **GHOSN M**, DROZ J.P. Compte rendu du Congrès de l'American Society of Clinical Oncology. (Tumeurs urologiques, Atlanta, 17-19 may 1987). *Journal d'Urologie (Paris)* 1987, N° 9-10, p 565 – 9. (Meeting report)
14. E. NASR, S. MERHEJ, D. NASR, G. FARES, M. MOUKARZEL, E. CHALOUHI, M. BULBUL, P. SARKIS, E. NEMR, M. JABBOUR, R. KHOURY, G. GHAZALE, G. CHEHADE, **M. GHOSN**, G. CHAHINE, A. ABILLAMAH. A five-year experience in conformational radiotherapy in the treatment of a prostate cancer. Evaluation of acute toxicity in 131 patients. *Progrès en Urologie* 2005; 15 (1): 36 – 9. (Original)
15. NASR F, CHAHINE G, KATTAN J, FARHAT F, TUEINI E, MOUKADEM W, DAGHER J, **GHOSN M**. Gemcitabine plus Carboplatinum (GC) Combination Therapy as Second Line Treatment in Relapsed Breast Cancer Patients. *Clinical Breast Cancer* 2004; 5 (2): 117-22. (Original)
16. SIBAI A, SHAMSUDDINE A, GEHCHAN N, RAHAL B, EL-SAGHIR N, **GHOSN M**, AFTIMOS G, CHAMSUDDINE N, SEOUD M, AUB MC Beirut, Lebanon. Cancer incidence in Postwar Lebanon: the first population-based estimates, 1993 and 1998. *Annals of Epidemiology* 2004; 14 (9): 663-8. (Original)
17. **GHOSN M**, KATTAN J. Weekly Chemotherapy in Metastatic Breast Cancer: the Ideamorphing (Quimioterapia seminal em câncer de mama). *Cancer Hôje* 2004; 2 (4):15-7. (article in Portuguese, review)
18. CHALHOUB-HACHEM BR, KATTAN JG, **GHOSN MG**, ABADJIAN GA, OKAIS NM. Departments of Hematology-Oncology, Pathology and Neuro-surgery, Hôtel-Dieu de France University Hospital, Beirut, Lebanon. Granulocytic sarcoma with spinal cord compression in chronic myelogenous leukemia: a case report. *Lebanese Medical Journal* 2003; 51 (2): 117-9. (Case report)

19. **GHOSN M.** KANSO CH, KATTAN J. CHAHINE G, TUEINI, NASSER E, YAZBECK P. Outcome of Cancer Patients admitted to the intensive care unit (ICU). *Lebanese Medical Journal*, 50 (4): 132-7. (Original)
20. EL MURR T, TOHME A, **GHOSN M.** GHAYAD E. Pseudomyxome péritonéal: A propos de deux cas et revue de la littérature. *Lebanese Medical Journal* 2002, 50 (4): 187-90. (Original)
21. EL MURR T, TOHME A, FARAH E, ABADJIAN G. **GHOSN M.** GHAYAD E. Vertebral actinomycosis: case report and review of the literature. *Lebanese Medical Journal* 2001, 49 (6): 355-8. (Original)
22. KATTAN J, FARAJ H, **GHOSN M.** CHAHINE G, ASSAF E, ABADJIAN G, KHOURY F. Mesothelioma-Asbestos in Lebanon: a problem to be considered. *Lebanese Medical Journal* 2001, 49 (6): 333 – 7. (Case /review)
23. ABOU CHACRA L, **GHOSN M.** GHAYAD E, HONEIN K. A case of pancreatitis associated with all-trans-retinoic acid therapy in acute promyelocytic leukemia. *The Hematology Journal (Haematologica)* 2001, 2: 406-7. (Case report)
24. KATTAN J, **GHOSN M.** Chemoprevention of breast cancer. Impact of a new therapeutic strategy. *Lebanese Medical Journal* 1999, 47 (5): 284 – 5. (Original)
25. KATTAN J, **GHOSN M.** Cancer in the elderly a special and unique entity. *Lebanese Medical Journal* 1997, 45 (3): 172 – 3. (Original)
26. **GHOSN M.** KATTAN J, NASR F. Retinoids in Chimioprévention. *Revue Médicale Libanaise* 1994, 6 (4): 242. (Original).
27. ABOUD B, SAYEGH R, CHAHINE G, **GHOSN M.** INGEA H, BIAJINI J, FARAH P. Métastase Gastriques du cancer du sein. *Presse Médicale* 1994, 23(38): 1758 – 9. (Original).
28. **GHOSN M.** DAGHER E, NASR F, CHAHINE G, TALEB N, NASNAS R, GHAYAD E. Infections in cancer patients with granulocytopenia. Retrospective studies of 59 febrile episodes with hospitalization. *Lebanese Medical Journal* 1994, 42 (3): 117 - 22. (Original).
29. MORAN-RIBON, J.P. DROZ, J. KATTAN, B. LECLERCQ, **M. GHOSN.** D. COUANET, M.OSTRONOFF, S. CULINE, B. MISSET, B. ESCUDIER, R. RUFFIE, G. NITENBERG. Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases. *Supportive Care in Cancer* 1994, 2: 253 - 8. (Report of 11 cases).
30. **GHOSN M.** TALEB N. Compte rendu de réunion : 1er Congrès d'Oncologie du Moyen-Orient, Beyrouth, Liban, 7 - 10 Juillet 1993. *Bulletin du Cancer* 1994, 81: 157 – 9. (Meeting report).
31. **GHOSN M.** GANNAGE M. Cancer Pain: Pharmacological Management (second of two parts). *Lebanese Medical Journal* 1993, 42 (4): 244 – 8. (Original).
32. **GHOSN M.** GANNAGE M. Cancer Pain: Pharmacological Management (first of two parts). *Lebanese Medical Journal* 1993, 41 (3): 174 – 6. (Original)
33. **GHOSN M.** CHOUEIFATY N. Greffe de Moëlle Osseuse : Allogreffe et Autogreffe. *Le Monde Médical* 1993, 10 (4): 29 - 44. (Original)
34. AZOURI J, AFIF N, **GHOSN M.** NADER N, BOU SABA C. Primary breast lymphoma. A case report. *Lebanese Medical Journal* 1992, 40 (4): 202 - 6. (Original)
35. HABIB C, KARAM S, KHALED H, RUSTOM R, GUEUTCHERIAN Y, AKATCHERIAN R, **GHOSN M.** Handling of antineoplastic products and nurses 'Knowledge. *Lebanese Medical Journal* 1992, 40 (4): 182 - 6. (Original)
36. BIAGINI J, SAYEGH R, **GHOSN M.** Therapeutic problem posed by Gardner's syndrome, report of a Lebanese family. *Lebanese Medical Journal* 1992, 40 (4): 182-6. (Original)
37. **GHOSN M.** DROZ J.P. The use of antiemetics in cancer chemotherapy. *Lebanese Medical Journal* 1992, 40 (2): 93-5. (Original)
38. MAHJoubi M, KATTAN J, **GHOSN M.** DROZ J.P, PHILIPPOT I, HERAIT P. Phase II trial of pirarubicin in the treatment of advanced bladder cancer. *Invest New Drugs* 1992, 10 (4): 317 – 21. (Original)
39. DROZ J.P, PICO J.L, **GHOSN M.** KRAMAR A, REY A, OSTRONOFF M, BAUME D. A phase II trial of early intensive chemotherapy with autologous bone marrow transplantation in the treatment of poor prognosis non seminomatous germ cell tumors. *Bulletin du Cancer* 1992, 79: 497 - 507. (Original)
40. ROUGIER Ph, AMMARGUELLAT H, **GHOSN M.** PIOT G, BENHAMED M, TIGAUD J.M, LAPLAIGE Ph, THEODORE C, KAC J, GOLDBERG J, CARDE P, DROZ J.P. Phase II trial of 7-Day continuous 5-Fluorouracil Infusion in the treatment of advanced colorectal carcinoma. *Oncology* 1992, 49 (1): 35 – 9. (Original)